onyx-pharma.dz Listed by darkpower Ransomware Group: Ransomware Claim — What’s Alleged & What To Do

On March 11, 2023, the Algerian pharmaceutical entity onyx-pharma.dz was listed on the leak site operated by the darkpower ransomware group. The group claims to have stolen internal data in a ransomware attack that involved exfiltration of internal files. The number of people affected remains unknown, and public detail on the incident is limited to this listing and the group's assertion.

For an organisation operating in the pharmaceutical sector, any claim of internal-file theft raises immediate questions about operational continuity, regulatory exposure, and the potential downstream risk to partners, staff, or patients whose information might appear in such material. What is confirmed so far is only the listing itself and the nature of the claim; independent verification of the volume, sensitivity, or full contents of the data has not been publicly established.

Inside the incident

According to available reporting, onyx-pharma.dz appeared on darkpower's ransomware leak site on or around March 11, 2023. The group states that it conducted a ransomware attack and exfiltrated internal files. No public information has been released regarding the precise date the intrusion began, how long the attackers remained inside the network, which systems were encrypted, or whether a ransom demand was issued or paid. The scale of the incident—measured in records, file volume, or individuals affected—is undisclosed. Method of initial access is likewise unconfirmed. The sole concrete public marker is the leak-site listing and the accompanying claim that internal data was taken.

The group behind it: darkpower

Darkpower is a ransomware operation that has appeared in public threat-intelligence reporting as a group that combines data theft with encryption, a double-extortion model now common among ransomware actors. Such groups typically gain access through compromised credentials, unpatched remote services, or phishing, then move laterally, exfiltrate selected files, and deploy ransomware before posting victims on a dedicated leak site to pressure payment. Darkpower's listings function as public claims rather than independently audited disclosures; the appearance of a victim name indicates the group asserts responsibility and possession of data, not that every asserted detail has been verified by the victim or by outside investigators. No statements attributed to darkpower beyond the general claim of having stolen internal data from onyx-pharma.dz are part of the public record of this incident.

Who is onyx-pharma.dz?

Onyx-pharma.dz is a pharmaceutical organisation based in Algeria, operating under the .dz country-code domain. Entities in this sector typically manufacture, distribute, or market medicines and related healthcare products. They routinely hold a mix of proprietary formulation data, supply-chain and pricing information, employee records, regulatory correspondence, and sometimes limited patient or prescriber data tied to pharmacovigilance or clinical activities. A breach affecting such an organisation is consequential because pharmaceutical operations sit at the intersection of public health, commercial confidentiality, and regulated personal information. Disruption or leakage can affect manufacturing schedules, partner trust, and compliance obligations under local and international data-protection and pharmaceutical-quality rules.

The information in question

The facts state that internal files were exfiltrated in a ransomware attack. No further breakdown—such as whether the material included employee databases, customer lists, financial ledgers, research documents, or system backups—has been publicly disclosed. Organisations of this type commonly store human-resources files, contracts, inventory systems, quality-control records, and correspondence with regulators and distributors. Because the exact contents remain unconfirmed, it is not possible to state which specific categories of personal or commercial data, if any, are involved. The claim is limited to “internal files,” and readers should treat any more granular description as speculative until corroborated.

Why it matters

For individuals whose details might appear in internal pharmaceutical files—employees, contractors, or business contacts—the practical risks include targeted phishing that references real internal projects, credential stuffing if work email addresses and passwords were stored together, and longer-term identity or employment-related fraud. For the organisation, consequences can include operational downtime, costs of forensic investigation and system rebuilding, potential regulatory scrutiny, and erosion of confidence among suppliers and healthcare partners. Even when the full scope is unknown, the mere public listing by a ransomware group creates a window in which criminals may attempt to monetise any data they hold or to impersonate the company. The absence of confirmed victim counts does not eliminate these risks; it simply means the perimeter of exposure has not yet been mapped in public sources.

What to do if you're exposed

If you have a past or present relationship with onyx-pharma.dz—as staff, supplier, or correspondent—monitor account activity on any email addresses or services tied to that relationship. Change passwords on related accounts, enable multi-factor authentication where available, and treat unexpected messages that reference internal company matters with caution. Review financial and credit statements for unfamiliar activity if you ever shared identity documents or banking details with the organisation. Keep records of any suspicious contact. As a further step, you can run a free exposure scan of your email address to check whether it has already appeared in known breach datasets, which provides an additional signal while official confirmation of this incident's full contents remains limited.

AICompiled with AI assistance from public sources and published under our editorial standards.